At present, as a result of a larger study, the fact that galectin-3 in serum in patients with AF and MS is higher than in healthy subjects was confirmed, however, it was also found that this biomarker is higher in patients with AF and MS than in patients with MS without given arrhythmia. This evidence concerns the gene LGALS3 and atrial fibrillation.